Incidence of brain metastases in HER2+ gastric or gastroesophageal junction adenocarcinoma

Gastric or gastroesophageal junction (GEJ) adenocarcinoma represents a major health issue, being the 3rd cause of death by cancer in the world. In industrialized countries, the incidence of GEJ cancers continues to rise, while gastric cancers have declined over the past few decades.The human epiderm...

Full description

Saved in:
Bibliographic Details
Published in:Acta oncologica 2015-11, Vol.54 (10), p.1833-1835
Main Authors: Blay, Christophe, Chiforeanu, Dan Cristian, Boucher, Eveline, Cabillic, Florian, Desgrippes, Romain, Leconte, Bérengère, Perrin, Christophe, Manfredi, Sylvain, Audrain, Odile, Meunier, Bernard, Edeline, Julien
Format: Article
Language:English
Subjects:
Adenocarcinoma - chemistry
Adenocarcinoma - genetics
Adenocarcinoma - secondary
Adult
Aged
Aged, 80 and over
Brain Neoplasms - secondary
Disease-Free Survival
Esophagogastric Junction
Female
Gene Amplification
Humans
Life Sciences
Male
Middle Aged
Peritoneal Neoplasms - secondary
Receptor, ErbB-2 - analysis
Receptor, ErbB-2 - genetics
Retrospective Studies
Stomach Neoplasms - chemistry
Stomach Neoplasms - genetics
Stomach Neoplasms - pathology
Survival Rate
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gastric or gastroesophageal junction (GEJ) adenocarcinoma represents a major health issue, being the 3rd cause of death by cancer in the world. In industrialized countries, the incidence of GEJ cancers continues to rise, while gastric cancers have declined over the past few decades.The human epidermal growth factor 2 (HER2) gene is a well-described proto-oncogene. HER2 gene amplification and protein overexpression have been mostly studied in breast cancer, where HER2 overexpression was reported in 15-20% of cases.In breast cancer, HER2 overexpression is associated with a higher risk of brain metastases and significantly worse survival [1]. The prognostic value of HER2 overexpression in gastric and GEJ adenocarcinomas remains controversial. A recently published systematic review was inconclusive in patients after curative surgery [2]. The standard of care in advanced gastric carcinoma patients has changed recently, with the results of the ToGa phase III trial adding trastuzumab to chemotherapy in patients with HER2 overexpression [3]. The study indicated that this subgroup of patients benefit from trastuzumab with a three months improvement of overall survival.The aim of this study was to seek if the correlation between HER2 overexpression and brain metastases exists in gastric or GEJ adenocarcinomas, where brain metastases are uncommon.
ISSN:0284-186X
1651-226X
DOI:10.3109/0284186X.2015.1011757